Remove Insurance Coverage and Processing Remove Packaging Remove Presentation
article thumbnail

Budget expectation: Bring GST rate on APIs at par with the formulations

Express Pharma

Expectation #2: Bring GST rate on APIs at par with the formulations – At present, APIs attract a higher GST rate of 18 per cent vis-à-vis formulations that attract a lower rate (12 per cent/5 per cent), leading to accumulation of credit for the pharma industry.

article thumbnail

Clinical trials for rare diseases

European Pharmaceutical Review

Measuring treatment effect in rare disease populations presents many methodological challenges due to small sample sizes and heterogeneity of the study population. How does the qualification package support more meaningful endpoints and rare disease research as a result?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

NHC Comments on Medicare Prescription Payment Plan

Putting Patients First Blog

The NHC supports the development and use of processes and tools that enhance beneficiary experience, making interactions with the MPPP smoother and more intuitive for all beneficiaries. Similarly, updating the Explanation of Benefits to include visual aids and examples will clarify MPPP’s impact on cost-sharing and coverage.

article thumbnail

NHC Comments on Medicare Prescription Payment Plan

Putting Patients First Blog

The NHC supports the development and use of processes and tools that enhance beneficiary experience, making interactions with the MPPP smoother and more intuitive for all beneficiaries. Similarly, updating the Explanation of Benefits to include visual aids and examples will clarify MPPP’s impact on cost-sharing and coverage.

article thumbnail

How early planning leads to successful market access and drug launch in Europe

Pharmaceutical Technology

Launching a new drug can be a risky business, with regulatory approval no guarantee that private, commercial, and government-funded insurers will reimburse it. Meanwhile, in Germany, the AMNOG process is conducted twelve months after the drug is launched, thus giving freedom to the company to set the drug’s price during this period.